A Phase 1b Multicenter, Open-Label, Single Ascending Dose Study to Evaluate the Safety and Tolerability of PF-06939926 in Ambulatory Subjects with Duchenne Muscular Dystrophy" Protocol # C3391001 (hereinafter the "Study")

Administered By

Awarded By

Contributors

Start/End

  • November 27, 2017 - December 31, 2023